GlassScriptPhysician profile
William L Smits
NPI 1811950462
$203,025.52
in general payments reported to CMS, 2019-2025
52 companies · $23K in 2025
The $23K reported for 2025 was more than what 93% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $35K · 2021: $50K · 2022: $16K · 2023: $9,154 · 2024: $28K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $49K · Food and Beverage: $10K · Travel and Lodging: $722 · Education: $124 · Consulting Fee: $64.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,525.00 |
| Food and Beverage | $10,494.06 |
| Travel and Lodging | $721.58 |
| Education | $124.47 |
| Consulting Fee | $64.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $91,282.09 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $23,870.89 | 2019-2025 | Dupixent |
| Abbvie INC. | $22,096.31 | 2021-2025 | Rinvoq, Ubrelvy, Qulipta |
| Allergan, INC. | $15,188.78 | 2020-2021 | |
| Optinose US, INC. | $11,945.73 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,685.12 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $10,031.80 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Novartis Pharmaceuticals Corporation | $8,051.41 | 2019-2025 | |
| Genzyme Corporation | $1,582.46 | 2019-2025 | |
| Pfizer INC. | $1,079.84 | 2019-2025 | |
| Grifols USA, LLC | $932.90 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Teva Pharmaceuticals USA, INC. | $811.55 | 2019-2025 | Ajovy |
| Csl Behring | $695.28 | 2019-2025 | Hizentra |
| Amgen INC. | $659.92 | 2019-2025 | Tezspire, Aimovig |
| Takeda Pharmaceuticals U.S.A., INC. | $533.25 | 2020-2025 | Glassia, Cuvitru, Eohilia |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Smits listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.